非那雄胺联合特拉唑嗪治疗良性前列腺增生症伴慢性前列腺炎60例疗效观察

CLINICAL EFFECTS OF FINASTERIDE COMBINED TERAZOSIN ON BENIGN PROSTATIC HYPERPLASIA WITH CHRONIC PROSTATITIS

目的观察非那雄胺联合特拉唑嗪治疗良性前列腺增生症伴慢性前列腺炎的临床疗效。方法选择临床确诊的良性前列腺增生伴慢性前列腺炎患者60例,口服非那雄胺(5mg/d)和特拉唑嗪(2mg/d)3个月,在治疗前和治疗3个月后分别检查国际前列腺症状评分(IPSS)、尿流率、残余尿量、前列腺体积、前列腺液常规。结果治疗后IPSS平均降低28.7%,最大尿流率平均升高37.4%,残余尿量平均减少40.5%,前列腺体积平均缩小18.1%,前列腺液中白细胞计数平均减少37.3%。前列腺液检查好转率56.7%,其中前列腺体积≥40ml组和<40ml组的前列腺液检查好转率分别为69.4%及37.5%,二组间比较差异有统计学意义(P<0.05)。结论非那雄胺联合特拉唑嗪可有效治疗伴慢性前列腺炎的良性前列腺增生症,对前列腺体积较大者效果更好。

Objective To observe the clinical efficacy of finasteride combined terazosin on benign prostatic hyperplasia （]3PH） with chronic prostatitis （CP）. Methods 60 patients with BPH and CP had received oral administration of finasteride （5 mg/d） and terazosin （2mg/d） for 3 months. IPSS, urine flow rate, residual urine volume, prostatic volume and expressed prostatic secretion （EPS） were detected before and after treatment. Results After treatment, maximal urine flow rate increased by 37.4%, but IPSS, residual urine volume, prostatic volume and leucocyte count in EPS decreased by 28.7%, 40.5%, 18.1% and 37.3% on average, respectively. Total improvement rate of EPS examination was 56.7%, but the improvement rate in patients with prostatic volume ≥40ml was superior to that in patients with prostatic volume （ 40ml （ 69.4% vs 37.5 %, P〈0.05 ）. Conclusion Combined use of inasteride and terazosin is effective for treating patients with BPH and CP,especially for those with bigger prostate.